Oncology Central

Is there an accurate biomarker test for thyroid cancer recurrence on the horizon?


Patients who are diagnosed with differentiated thyroid cancer (DTC) have favorable survival rates of over 90%; however, up to 30% of them develop recurrent disease leading to considerable morbidity [1]. Multiple prognostic systems have been developed for thyroid cancer, which are effective in predicting mortality, but not as effective in predicting recurrence [2].

To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.